• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology



This novel dyslipidemia therapy features a combination of 2 previously approved drugs: ezetimibe and simvastatin. Ezetimibe exerts its effect by selectively inhibiting intestinal cholesterol and related phytosterol absorption. This mechanism of action is complemented by that of simvastatin, which acts through inhibition of the HMG-CoA reductase enzyme. The ezetimibe/simvastatin combination was approved on July 23, 2004, for the treatment of hypercholesterolemia and mixed hyperlipidemia

© 2024 MJH Life Sciences

All rights reserved.